Eisai Co. Ltd. ADR

OTC: ESALY

GO
/marketstate/country/us

Market closed

/zigman2/quotes/202565502/delayed

$

76.52

Change

-1.24 -1.59%

Volume

Volume 11,058

Sep 27, 2021, 3:58 p.m.

Quotes are delayed by 20 min

/zigman2/quotes/202565502/delayed

Previous close

$ 77.76

$ 76.52

Change

-1.24 -1.59%

Day low

Day high

$76.28

$77.50

Open
Open: 76.55

52 week low

52 week high

$62.13

$114.78

Open

Market cap

$22.39B

Average volume

38,117

P/E ratio

39.53

Rev. per Employee

$542,003

EPS

1.94

Dividend

0.73

Div yield

1.66%

Ex dividend date

3/29/21

Compare:
Indexes
  • Dow(INDU) INDU
  • Nasdaq (COMP) COMP
  • S&P 500 (SPX) SPX
  • Global Dow (GDOW) GDOW
1d
5d
3m
6m
1y
3y
5y
/news/latest/company/us/esaly

MarketWatch News on ESALY

  1. Only ‘greedy’ drug companies will cure Alzheimer’s

    1:12 p.m. June 12, 2021

    - Brett Arends

  2. Biogen's Alzheimer's Drug Is Approved by the FDA

    2:02 p.m. June 7, 2021

    - Barron's Online

  3. Biogen Stock Gains Before Anticipated FDA Decision

    11:12 a.m. June 7, 2021

    - Barron's Online

  4. What to Know About the FDA's Approval of Biogen's Alzheimer's Drug

    10:47 a.m. June 8, 2021

    - Barron's Online

  5. FDA's Call on Biogen's Alzheimer's Drug Is Coming Soon

    10:53 a.m. June 7, 2021

    - Barron's Online

  6. Don’t Expect Amazon Prime Day to Move the Stock

    8:26 a.m. June 2, 2021

    - Barron's Online

  7. The FDA's Biogen Decision Will Cause Waves Across Biotech

    9:20 p.m. June 1, 2021

    - Barron's Online

  8. Biogen’s Alzheimer’s Drug Faces a Big Test

    10:57 a.m. Feb. 11, 2021

    - Barron's Online

  9. Biogen says it will pursue FDA approval of early Alzheimer's drug

    6:39 a.m. Oct. 22, 2019

    - Steve Goldstein

  10. Merck Wins Approval for Cancer Treatment in 3 Countries at Once

    11:23 a.m. Sept. 18, 2019

    - Barron's Online

  11. Biogen, Eisai to discontinue phase 3 trial of oral BACE Alzheimer's treatment

    8:05 a.m. Sept. 13, 2019

    - Tomi Kilgore

  12. Health-care earnings: ‘Medicare for all’ looms large

    10:11 a.m. April 23, 2019

    - Sarah Toy

  13. Loading more headlines...

Analyst Ratings

/news/nonmarketwatch/company/us/esaly

Other News on ESALY

  1. Biogen, Eisai begin rolling submission of lecanemab BLA for early Alzheimer's disease

    1:51 a.m. Today

    - Seeking Alpha

  2. Eisai: Aduhelm Does Not Look Like A Major Drug Against Alzheimer's

    11:09 a.m. Sept. 20, 2021

    - Seeking Alpha

  3. How Keytruda's Latest Approval in China Boosts Merck

    9:18 a.m. Sept. 11, 2021

    - Motley Fool

  4. Merck Investors Have Reason to Cheer This Label Expansion

    6:37 a.m. Sept. 9, 2021

    - Motley Fool

  5. Citius (CTXR) Acquires Dr. Reddy's License for NHL Therapy

    11:34 a.m. Sept. 8, 2021

    - Zacks.com

  6. What This Label Expansion Means for Merck

    7:19 a.m. Aug. 22, 2021

    - Motley Fool

  7. VA Health System Won’t Cover Biogen’s Alzheimer’s Drug

    5:29 p.m. Aug. 12, 2021

    - Joseph Walker

  8. Loading more headlines...
/news/pressrelease/company/us/esaly

Press Releases on ESALY

  1. Alzheimer’s Disease Drug Market Size,Analysis,Outlook,Forecast 2020-2026

    7:23 a.m. Oct. 9, 2020

    - Market Insight Reports

  2. Loading more headlines...

Rates »

Trending Tickers
  • /zigman2/quotes/200467500/composite NVDA+6.01%
  • /zigman2/quotes/200164174/composite SNOA+85.40%
  • /zigman2/quotes/202092269/composite ENSC+35.46%
  • /zigman2/quotes/226465160/composite ALF-14.72%
  • /zigman2/quotes/207732364/composite MSFT+1.66%
X
Powered by StockTwits
Link to MarketWatch's Slice.